Abstract
Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Current Cancer Therapy Reviews
Title: NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Volume: 4 Issue: 2
Author(s): Renu Datta, Catherine L. Riley, Italo A. Dodi and Robert C. Rees
Affiliation:
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Abstract: Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Export Options
About this article
Cite this article as:
Datta Renu, Riley L. Catherine, Dodi A. Italo and Rees C. Robert, NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310133
DOI https://dx.doi.org/10.2174/157339408784310133 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SUI-Current Medicinal Therapeutic Options
Current Women`s Health Reviews Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Wet-lab Tested MicroRNA Assays for qPCR Studies with SYBR<sup>®</sup> Green and DNA Primers in Pig Tissues
MicroRNA PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry The Role of Apoptotic Dysfunction in the Pathogenesis of Endometriosis
Current Women`s Health Reviews Regulation of LDLR, Bcl-2 and FASN Expressions by Oxidized Low Density Lipoprotein in Estrogen Receptor Positive Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine 1,3,4-oxadiazole-2-thione Derivatives; Novel Approach for Anticancer and Tubulin Polymerization Inhibitory Activities
Anti-Cancer Agents in Medicinal Chemistry Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Preparation and Oxidation Chemistry of the Catechol Estrogens: Relevance to Estrogen-Related Carcinogenesis and Potential for Drug Design
Current Bioactive Compounds Toll-Like Receptors in the Cycling Female Reproductive Tract and During Pregnancy
Current Women`s Health Reviews Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Current Medicinal Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Challenge of Mesenchymal Stem Cells Against Diabetic Foot Ulcer
Current Stem Cell Research & Therapy Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry